IQ-AI Limited

Equities

IQAI

JE00BD4H0R42

Healthcare Facilities & Services

Market Closed - London S.E. 11:35:13 2024-05-03 am EDT 5-day change 1st Jan Change
1.6 GBX -5.88% Intraday chart for IQ-AI Limited 0.00% -65.96%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
EARNINGS AND TRADING: Trident Royalties swings to profit AN
IQ-AI Limited Provides Revenue Guidance for the Financial Year 2024 CI
IQ-AI Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
IQ-AI's Broker Exercises Option to Buy Shares in Placing MT
IQ-AI Plans Share Placing to Advance Oral Anti-tumor Agent Development MT
IQ-AI shares sink on discounted placing fundraise AN
IQ-AI Unit to Revise, Resubmit Pediatric Rare Disease Designation Application After US FDA Feedback MT
IQ-AI subsidiary asked by FDA to resubmit and modify application AN
IQ-AI Unit Secures Grant for Brain Tumor Pill Access Program MT
IQ-AI celebrates USD100,000 grant for subsidiary AN
IQ-AI falls after subsidiary notes launch of treatment access scheme AN
IQ-AI's Imaging Biometrics Plans Expanded Access Program for Brain Tumor Treatment MT
IQ-AI Subsidiary’s Glioblastoma Therapy Obtains Fast-Track Designation From US FDA MT
IQ-AI firm gets US FDA fast-track status for oral gallium maltolate AN
IQ-AI's Imaging Biometrics Discloses Positive Results in Early-stage Study of Potential Brain Cancer Treatment MT
IQ-AI stock rises on positive interim results from glioblastoma trial AN
IQ-AI Unit Seeks Pediatric Rare Disease Designation for Brain Tumor Treatment MT
IQ-AI says Imaging Biometrics submits paediatric rare disease request AN
IQ-AI Applies for FDA Pediatric Rare Disease Designation CI
IQ-AI subsidiary "central" to "landmark" brain cancer study AN
IQ-AI subsidiary wins orphan drug designation from US FDA AN
IQ-AI's Atypical Teratoid Rhabdoid Tumor Treatment Gains US FDA Orphan Drug Designation MT
IQ-AI Halts Trading on OTCQB Venture Market in US; London Shares Up 13% MT
IQ-AI Unit’s Study Validates IB Neuro Platform for Reduced Gadolinium Approach on 1.5T MR Scanners MT
IQ-AI notes vindication of subsidiary's reduced gadolinium approach AN
Chart IQ-AI Limited
More charts
IQ-AI Limited is a Jersey-based company, which is engaged in the provision of clinical treatments to patients in the field of medical imaging diagnostics, based on technology. The Company operates through two segments: holding company expenses and medical software. Its subsidiaries include Imaging Biometrics, LLC and Stone Checker Software Limited. Imaging Biometrics, LLC is a healthcare imaging software company. In addition to providing regulatory consulting services, Imaging Biometrics, LLC supplies medical technology solutions and has a neuroimaging product portfolio. Stone Checker Software Limited is a supplier of technology solutions in the field of kidney stone analysis and kidney stone prevention.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. IQAI Stock
  4. News IQ-AI Limited
  5. IQ-AI Plans Share Placing to Advance Oral Anti-tumor Agent Development